- News Releases
-
- Jun. 23, 2021 (PDF/221KB)Products
- Poxel and Sumitomo Dainippon Pharma Announce the Approval of TWYMEEG (Imeglimin hydrochloride) for the Treatment of Type 2 Diabetes in Japan
-
- Jun. 09, 2021 (PDF/163KB)Licensing
- Chemiphar and Sumitomo Dainippon Pharma Conclude Collaborative Research and Development Agreement and Option Agreement for Novel Antidepressant/Anxiolytic Candidate Compound "NC-2800"
-
- Jun. 03, 2021 (PDF/74KB)Corporate
- Comments Regarding Media Article on Our Company
-
- May 27, 2021 (PDF/172KB)Products
- Myovant Sciences and Pfizer Receive FDA Approval for MYFEMBREE, the First Once-Daily Treatment for Heavy Menstrual Bleeding Associated With Uterine Fibroids
-
- May 24, 2021 (PDF/40KB)R&D
- Myovant Sciences Receives Positive CHMP Opinion for RYEQO (Relugolix Combination Tablet) for the Treatment of Women With Uterine Fibroids
Other Notices
-
- Jun. 24, 2021Corporate (PDF/103KB)
- Sumitomo Dainippon Pharma Announces Release of Movie on Change of Company Name
-
- Mar. 25, 2021Corporate (PDF/129KB)
- Sumitomo Dainippon Pharma Announces the Launch of Website Dedicated to Frontier Business
IR Library
-
Change company name from April 2022
-
Continuing to challenge ourselves to support a healthy future for people
-
Aiming to create innovative pharmaceutical products
-
Targeting sustainable growth
-
Leading our global expansion
-
Thinking BEYOND medication